Oxigene: Combination therapy suppresses tumor regrowth in animals

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Oxigene, Inc. published the results of a preclinical study evaluating the combination of vascular disrupting agents with an antiangiogenic drug to enhance suppression of tumor growth in mice.

Using the antiangiogenic drug DC101 24 hours prior to administration of either of the Waltham, Mass.-based pharmaceutical company's vascular disrupting agents, Combretastatin-A4 phosphate (CA4P) or OXi-4503, resulted in markedly enhanced antitumor activity in the study, according to a company release.

The company said vascular disrupting agents such as its CA4P and OXi-4503 have been shown to cause rapid occlusion of existing tumor blood vessels, which leads to massive intratumoral necrosis. However, vascular disrupting agent-treated tumors can regrow in the tumor periphery, a regrowth thought to be caused in part by an acute mobilization of circulating endothelial progenitor cells.

The company added that antiangiogenic drugs such as DC101 inhibit growth of new blood vessels and disrupt the acute mobilization and levels of circulating endothelial progenitor cells.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.